External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology APPLE 2023
Roche and Genentech at

APPLE 2023

July 06 - July 08
Seoul, Korea
apple2023
Add to calendar
Share feedback
Share page
-
Medical Materials
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Jul 7 / Roche and Genentech
IMbrave050: Adjuvant Atezolizumab+Bevacizumab vs Active Surveillance in Hepatocellular Carcinoma Patients at High Risk of Disease Recurrence Following Resection or Ablation
Currently, no standard of care exists in the adjuvant setting for hepatocellular carcinoma following resection or ablation with curative intent. Here we report the patient-reported outcome (PRO) data from IMbrave050, a global, open-label, Phase 3, randomized study of atezolizumab + bevacizumab vs active surveillance in patients at high risk of disease recurrence following resection or ablation with curative intent.
Oncology Gastrointestinal Cancer APPLE-2023

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.